Chugai Pharmaceutical (OTCMKTS:CHGCY) Stock Price Down 0.4% - Here's Why

Key Points

• Chugai Pharmaceutical's shares decreased by 0.4%, trading between $21.28 and $21.89 with a significant drop in trading volume, down 67% from average levels.
• The company reported $0.20 EPS and $2.01 billion in revenue for the last quarter, with analysts projecting a total earnings per share of 0.74 for the fiscal year.
• Chugai Pharmaceutical has a market cap of $72.04 billion and a PE ratio of 27.71, indicating a stable performance amidst market fluctuations.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) traded down 0.4% on Friday . The company traded as low as $21.28 and last traded at $21.89. 79,633 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 240,106 shares. The stock had previously closed at $21.97.

Chugai Pharmaceutical Stock Performance

The stock has a market cap of $71.55 billion, a PE ratio of 27.52 and a beta of 0.64. The stock has a fifty day simple moving average of $23.17 and a two-hundred day simple moving average of $24.61.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its earnings results on Thursday, July 24th. The company reported $0.20 EPS for the quarter. The company had revenue of $2.01 billion during the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%. On average, equities analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.